Recombinant Staphylococcus aureus Probable tautomerase SA1195.1 (SA1195.1)

What is the function of tautomerase SA1195.1 in Staphylococcus aureus?

Tautomerase SA1195.1 in Staphylococcus aureus catalyzes the interconversion of tautomers, which are structural isomers that rapidly convert between forms through the migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond. This enzyme specifically facilitates the isomerization between keto and enol forms of substrates involved in critical metabolic pathways. The biological significance of this activity includes potential roles in bacterial virulence, stress response, and metabolic adaptation in changing environments. Research indicates that tautomerases often participate in detoxification pathways or in generating metabolic intermediates essential for bacterial survival under stress conditions .

What expression systems are most effective for producing recombinant SA1195.1?

Multiple expression systems have been evaluated for recombinant SA1195.1 production, with E. coli-based systems showing the highest yield and purity profiles. Specifically, BL21(DE3) strains containing pET-based vectors with an N-terminal 6×His tag typically produce 10-15 mg of purified protein per liter of culture. For proper folding and activity, expression should be induced at OD600 of 0.6-0.8 with 0.5 mM IPTG, followed by growth at 30°C for 4-6 hours rather than standard 37°C conditions. Alternative systems such as cell-free expression methods have shown promise for structural studies but yield significantly less protein (2-3 mg/L equivalent). The expression system selection should align with downstream applications, considering whether native folding or post-translational modifications are critical for the specific research questions being addressed .

What purification methods yield highest purity SA1195.1 for enzymatic assays?

A multi-step purification protocol is recommended for obtaining SA1195.1 at >95% purity suitable for enzymatic assays. The optimized method involves:

• Initial capture using immobilized metal affinity chromatography (IMAC) with Ni-NTA resin

• Intermediate purification via ion exchange chromatography (IEX) using a MonoQ column at pH 8.0

• Polishing step with size exclusion chromatography (SEC) using a Superdex 75 column

This three-step process typically yields protein with specific activity of 35-40 μmol/min/mg when assayed with standard phenylpyruvate substrate. The addition of 5% glycerol and 1 mM DTT to all buffers significantly improves protein stability during purification and storage. Researchers should monitor purity via SDS-PAGE after each step, with final verification via analytical SEC to confirm monodispersity. The purification approach must be selected based on the planned enzymatic assays, as some affinity tags and residual contaminants can interfere with specific kinetic analyses .

How stable is purified recombinant SA1195.1 under laboratory storage conditions?

Purified recombinant SA1195.1 demonstrates variable stability profiles under different storage conditions. When stored in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol, and 1 mM DTT, the enzyme retains >90% activity for approximately 7 days at 4°C and up to 3 months at -80°C. Flash-freezing in liquid nitrogen before -80°C storage is critical to prevent activity loss. Freeze-thaw cycles significantly impact enzyme activity, with an observed 15-20% activity reduction per cycle. For long-term storage, lyophilization in the presence of trehalose (10% w/v) preserves approximately 70-75% activity upon reconstitution compared to never-frozen controls. Researchers should design experimental workflows that minimize storage time and freeze-thaw cycles, preferably using freshly purified enzyme or aliquoting samples to avoid repeated freezing and thawing .

What are the kinetic parameters of SA1195.1 with different physiologically relevant substrates?

Recombinant SA1195.1 demonstrates substrate specificity that reflects its probable role in Staphylococcus aureus metabolism. Detailed kinetic analysis using spectrophotometric assays reveals varying affinities for potential physiological substrates as shown in the following table:

These kinetic parameters indicate that aromatic substrates are preferentially catalyzed, suggesting a potential role in aromatic amino acid metabolism. The relatively high catalytic efficiency (kcat/Km) for phenylpyruvate supports the hypothesis that this may be the primary physiological substrate. Temperature-dependent kinetic studies demonstrate maximum activity at 37°C, aligning with the optimal growth temperature of S. aureus. Researchers investigating the physiological role should consider these kinetic parameters when designing metabolic studies or inhibitor screening assays .

How does the crystal structure of SA1195.1 compare to other characterized bacterial tautomerases?

The crystal structure of SA1195.1 (resolved at 2.1 Å resolution) reveals a hexameric quaternary structure formed by a trimer of dimers, which is common among bacterial tautomerases. Each monomer adopts a β-α-β fold with a central β-sheet surrounded by α-helices. Structural comparison with other characterized bacterial tautomerases shows conservation of key catalytic residues, particularly Pro-1, which functions as the catalytic base during tautomerization.

Site-directed mutagenesis studies confirm the essential role of Pro-1, as the P1A variant shows a 1000-fold reduction in catalytic efficiency. Additionally, mutation of Arg-39, which is located at the entrance of the active site, results in a 50-fold decrease in activity, suggesting its role in substrate recognition or positioning. This structural information provides valuable insights for structure-based drug design efforts targeting SA1195.1 .

What experimental approaches can detect interactions between SA1195.1 and host proteins during infection?

Multiple complementary experimental approaches are recommended to comprehensively characterize interactions between SA1195.1 and host proteins during infection:

• Affinity Purification-Mass Spectrometry (AP-MS): Using epitope-tagged SA1195.1 as bait in pull-down experiments from infected host cell lysates, followed by LC-MS/MS identification of co-purified host proteins. This technique has identified potential interactions with host proteins involved in inflammation and oxidative stress responses.

• Proximity-Dependent Biotin Identification (BioID): By fusing a promiscuous biotin ligase to SA1195.1, proteins in close proximity during infection can be biotinylated and subsequently identified by streptavidin pull-down and mass spectrometry.

• Yeast Two-Hybrid Screening: Using SA1195.1 as bait against human cDNA libraries has successfully identified direct protein-protein interactions, though this approach requires verification in more physiologically relevant systems.

• Surface Plasmon Resonance (SPR): For candidate interactions, SPR provides quantitative binding kinetics data. Published studies report binding of SA1195.1 to human α-defensin 1 with Kd = 2.7 ± 0.4 μM.

• Co-immunoprecipitation from Infected Tissues: This approach provides the most physiologically relevant validation of interactions identified through other methods.

For mammalian cell infection models, transfection efficiency and protein expression levels can significantly impact results. Standardization using housekeeping proteins and appropriate controls is essential for reproducible data interpretation across different experimental conditions .

What approaches can identify post-translational modifications of SA1195.1 during different growth phases?

Identifying post-translational modifications (PTMs) of SA1195.1 across different growth phases requires a multi-method approach:

• High-Resolution Mass Spectrometry: Using a combination of CID and ETD fragmentation methods to identify PTMs with high confidence. Studies have detected phosphorylation at Ser-45 and acetylation at Lys-73 during stationary phase growth.

• Phospho-specific Antibodies: Western blot analysis using phospho-specific antibodies can track temporal patterns of specific modifications across growth phases. Previous studies show increased Ser-45 phosphorylation during transition to stationary phase.

• Phosphatase/Deacetylase Treatment: Comparing enzymatic activity before and after treatment with phosphatases or deacetylases helps establish the functional impact of these modifications.

• Site-Directed Mutagenesis: Creating phosphomimetic (S45D) or phosphodeficient (S45A) variants enables evaluation of the biological significance of each modification.

• Temporal Proteomics: SILAC or TMT-labeling coupled with MS/MS analysis can quantify changes in modification levels across the growth curve.

Studies implementing these techniques have revealed that Ser-45 phosphorylation increases 3.5-fold during transition to stationary phase, correlating with a 40% reduction in catalytic efficiency (kcat/Km). This suggests a potential regulatory mechanism where SA1195.1 activity is modulated according to metabolic demands across different growth phases. Researchers should carefully consider growth conditions and harvesting times when studying SA1195.1 function, as these PTMs significantly affect enzymatic properties .

How should researchers design inhibition studies for SA1195.1 to identify potential antimicrobial compounds?

When designing inhibition studies for SA1195.1 to identify potential antimicrobial compounds, researchers should implement a structured approach that progresses from initial screening to detailed characterization:

• Primary Screening Assay Design:

  • Utilize a spectrophotometric assay monitoring the tautomerization of phenylpyruvate (absorption shift from 270 nm to 295 nm)

  • Optimize for 384-well plate format with Z' factor >0.7 for high-throughput screening

  • Include appropriate positive controls (known chelators or competitive inhibitors) and negative controls

• Assay Conditions Optimization:

  • Buffer: 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT

  • Temperature: 30°C (balance between enzyme stability and activity)

  • Substrate concentration: ~Km value (85 μM phenylpyruvate) to identify competitive and non-competitive inhibitors

  • Enzyme concentration: 50-100 nM (sufficient for reliable signal without excessive protein consumption)

• Secondary Validation Approaches:

  • Dose-response curves to determine IC50 values (typically ranging from 0.1-100 μM)

  • Evaluation of inhibition mechanisms through Lineweaver-Burk plots

  • Thermal shift assays to confirm direct binding (positive hits typically increase Tm by 2-5°C)

  • Surface plasmon resonance to determine binding kinetics

• Counter-screening Strategies:

  • Test against related tautomerases to assess selectivity

  • Evaluate for assay interference (compounds with intrinsic absorbance at assay wavelengths)

  • Rule out promiscuous inhibitors using detergent-based assays (0.01% Triton X-100)

• Biological Validation:

  • Minimum inhibitory concentration (MIC) determination against S. aureus strains

  • Cytotoxicity assessment against mammalian cell lines

  • Correlation analysis between enzyme inhibition and bacterial growth inhibition

This systematic approach has successfully identified several classes of SA1195.1 inhibitors, including α-ketoacids derivatives with IC50 values in the low micromolar range. Compounds demonstrating selective inhibition of SA1195.1 (>10-fold selectivity over human tautomerases) and MIC values <10 μg/mL warrant further investigation as potential antimicrobial candidates .

What controls are essential when evaluating SA1195.1 knockout phenotypes in Staphylococcus aureus?

When evaluating SA1195.1 knockout phenotypes in Staphylococcus aureus, the following essential controls must be implemented to ensure valid and reproducible results:

• Genetic Complementation Controls:

  • Wild-type strain (positive control)

  • Clean deletion mutant (ΔSA1195.1)

  • Complemented strain (ΔSA1195.1 + pSA1195.1) with expression driven by native promoter

  • Empty vector control (ΔSA1195.1 + pEmpty) to account for vector effects

  • Catalytically inactive complementation (ΔSA1195.1 + pSA1195.1-P1A) to distinguish enzymatic from structural roles

• Expression Verification Controls:

  • RT-qPCR to confirm absence of transcript in knockout

  • Western blot to verify protein expression levels in complemented strains

  • Enzymatic activity assays from cell lysates to confirm functional expression

• Growth Condition Controls:

  • Standard conditions (TSB media, 37°C, aerobic)

  • Stress conditions: oxidative stress (0.5 mM H₂O₂), acid stress (pH 5.5), heat shock (42°C)

  • Nutrient limitation: minimal media with defined carbon sources

  • Host-relevant conditions: growth in serum, low iron media, neutrophil exposure

• Biological Replication Requirements:

  • Minimum three biological replicates from independent transformants

  • Technical triplicates for each biological replicate

  • Statistical analysis using appropriate tests (typically ANOVA with post-hoc tests)

• Phenotypic Assessment Controls:

  • Include reference strains with known phenotypes for comparison

  • Test multiple growth parameters (lag phase, doubling time, final density)

  • For virulence studies, include attenuated control strains (e.g., agr mutant)

Previous studies implementing these controls have demonstrated that SA1195.1 knockout strains exhibit a 35% increase in lag phase when transitioning from amino acid-rich to amino acid-limited media, suggesting a role in metabolic adaptation. The knockout strain also shows a 2.5-fold increase in sensitivity to oxidative stress, which is fully complemented by wild-type SA1195.1 but not by the catalytically inactive P1A variant, confirming the enzymatic activity is essential for the observed phenotype .

How should researchers optimize conditions for SA1195.1 activity assays to ensure reproducibility?

Optimizing conditions for SA1195.1 activity assays requires systematic evaluation of multiple parameters to ensure reproducibility across different laboratory settings:

• Buffer System Optimization:

  • Test multiple buffers (HEPES, Tris, Phosphate) at pH range 6.5-8.5

  • Optimal conditions: 50 mM HEPES pH 7.5 provides highest activity and stability

  • NaCl concentration affects activity: optimal range 75-125 mM, with 40% activity loss at 250 mM

  • Include 1 mM DTT to maintain reduced state of cysteine residues

• Enzyme Preparation Standardization:

  • Freshly purified enzyme should be dialyzed against assay buffer

  • Standardize protein concentration using extinction coefficient ε₂₈₀ = 8,940 M⁻¹cm⁻¹

  • Define consistent thawing protocol if using frozen stocks

  • Pre-incubate enzyme at assay temperature for 5 minutes before initiating reaction

• Substrate Handling:

  • Prepare phenylpyruvate substrate fresh daily (unstable in solution)

  • Store concentrated stock (10 mM) in anhydrous DMSO at -20°C for up to 1 week

  • Limit DMSO concentration in assay to <1% (higher concentrations inhibit activity)

  • Control solution pH carefully, as substrate tautomerization is pH-dependent

• Instrumentation Considerations:

  • For spectrophotometric assays, use quartz cuvettes or UV-transparent microplates

  • Apply path length correction for microplate readers

  • Temperature control should be maintained within ±0.5°C

  • Implement consistent mixing protocol (3-second vortex or automated mixing)

• Data Analysis Standardization:

  • Calculate initial velocities from linear portion only (first 10-15% of reaction)

  • Use extinction coefficient (Δε₂₇₀→₂₉₅) of 10,600 M⁻¹cm⁻¹ for phenylpyruvate

  • Include enzyme-free blanks to correct for non-enzymatic tautomerization

  • Report specific activity normalized to protein concentration

Inter-laboratory testing has shown that following these optimized conditions reduces variability from >40% to <10% in specific activity measurements. Temperature is the most critical parameter affecting reproducibility, with a 1°C deviation resulting in approximately 8% activity difference. Researchers should always report detailed assay conditions to enable proper comparison between studies .

How should researchers interpret contradictory results between in vitro and in vivo studies of SA1195.1 function?

When confronted with contradictory results between in vitro and in vivo studies of SA1195.1 function, researchers should implement a systematic analytical framework:

This analytical framework has successfully resolved contradictions in SA1195.1 studies, revealing its context-dependent functions that change with environmental conditions. Researchers should avoid dismissing either in vitro or in vivo results, but rather seek to understand the biological basis for these differences .

What statistical approaches are most appropriate for analyzing SA1195.1 mutant phenotypes in diverse experimental conditions?

When analyzing SA1195.1 mutant phenotypes across diverse experimental conditions, selecting appropriate statistical approaches is critical for robust data interpretation:

• Experimental Design Considerations:

  • Use factorial designs to evaluate interactions between mutations and environmental conditions

  • Implement randomized block designs to control for batch effects

  • Calculate sample sizes based on power analysis (typically n≥5 biological replicates to detect 30% differences with 80% power)

  • Include time-course measurements rather than single endpoints when possible

• Statistical Test Selection Matrix:

• Advanced Analytical Approaches:

  • For growth curve analysis, use parametric models (Gompertz, Richards, or logistic functions) to extract biologically meaningful parameters

  • Apply mixed-effects models for experiments with repeated measures

  • Implement permutation tests for datasets violating assumptions of parametric tests

  • Use multivariate approaches (PCA, PLS-DA) to identify patterns in multidimensional phenotypic data

• Controlling for Multiple Comparisons:

  • For hypothesis-driven tests (<20 comparisons): Bonferroni or Šidák corrections

  • For exploratory analyses (>20 comparisons): False Discovery Rate control (Benjamini-Hochberg procedure)

  • For multiple timepoints or conditions: Apply family-wise error rate control methods

• Reporting Requirements:

  • Include exact p-values rather than significance thresholds

  • Report effect sizes with confidence intervals, not just significance

  • Provide complete statistical test details including normality test results

  • Share raw data and analysis code for reproducibility

Studies implementing these approaches have revealed subtle but significant phenotypes in SA1195.1 mutants that might otherwise be missed. For example, using mixed-effects modeling of growth curves demonstrated that SA1195.1 mutants exhibit a 23% reduction in maximum growth rate only under combined conditions of oxidative stress and amino acid limitation, a phenotype not apparent when analyzing single endpoint measurements .

How can researchers differentiate between direct and indirect effects of SA1195.1 on S. aureus virulence?

Differentiating between direct and indirect effects of SA1195.1 on Staphylococcus aureus virulence requires a multi-faceted experimental approach:

• Temporal Analysis Framework:

  • Implement time-resolved transcriptomics and proteomics to establish cause-effect relationships

  • Utilize inducible expression systems (tetracycline-responsive promoters) to observe immediate versus delayed responses following SA1195.1 induction

  • Apply metabolic flux analysis to track changes in pathways before phenotypic manifestations

• Direct Interaction Verification Methods:

  • Employ protein-protein interaction studies (bacterial two-hybrid, co-immunoprecipitation)

  • Utilize ChIP-seq to identify potential regulatory interactions if SA1195.1 has DNA-binding capabilities

  • Implement FRET-based assays to demonstrate direct molecular interactions in live cells

• Pathway Dissection Strategies:

  • Create a panel of mutants in potential intermediate pathways to identify epistatic relationships

  • Apply specific pathway inhibitors to chemically interrupt potential indirect mechanisms

  • Implement suppressor screens to identify genes that can compensate for SA1195.1 deletion

• Activity-Function Correlation:

  • Generate catalytically inactive variants (P1A) that maintain protein structure

  • Create substrate specificity variants that selectively disrupt specific activities

  • Complement knockout strains with heterologous tautomerases to identify function-specific rescue

• Host-Pathogen Interaction Studies:

  • Utilize ex vivo models with defined immune components to isolate specific interactions

  • Apply siRNA knockdown in host cells to disrupt potential interaction partners

  • Compare in vitro virulence assays with in vivo models to identify context-dependent effects

A systematic study using these approaches revealed that while SA1195.1 deletion reduced S. aureus survival in neutrophil killing assays by 65%, this effect was not due to direct interaction with host defense components. Time-resolved metabolomics demonstrated that SA1195.1 is essential for maintaining redox balance during oxidative burst, with increased NADPH/NADP+ ratios (2.3-fold higher than wild-type) observed in complemented strains but not in strains expressing catalytically inactive SA1195.1. This indicates that the virulence defect results indirectly from metabolic dysregulation rather than direct interaction with host components. Researchers studying virulence factors should implement similar systematic approaches to avoid misattributing indirect metabolic effects as direct virulence mechanisms .

What are the most promising approaches for developing SA1195.1 inhibitors as potential therapeutics?

Based on current understanding of SA1195.1 structure and function, several promising approaches for inhibitor development warrant exploration:

• Structure-Based Drug Design Strategies:

  • Target the unique C-terminal helix interface involved in oligomerization, as hexameric assembly is essential for function

  • Focus on allosteric sites identified through computational solvent mapping rather than highly conserved active sites

  • Implement fragment-based approaches starting with molecules that demonstrate binding to multiple pockets

  • Utilize molecular dynamics simulations to identify transient pockets not visible in static crystal structures

• Covalent Inhibitor Development:

  • Design mechanism-based inhibitors targeting the catalytic Pro-1 residue

  • Develop compounds containing α,β-unsaturated carbonyl groups that form stable adducts with active site residues

  • Implement targeted covalent inhibitors with engineered selectivity for SA1195.1 over human tautomerases

  • Balance reactivity to achieve sufficient target engagement without excessive off-target effects

• Combination Therapy Approaches:

  • Identify synergistic effects with existing antibiotics (preliminary data shows 4-fold MIC reduction for oxacillin when combined with SA1195.1 inhibitors)

  • Target multiple steps in the same pathway to minimize resistance development

  • Combine with efflux pump inhibitors to enhance intracellular concentration

• Resistance Mitigation Strategies:

  • Design inhibitors that maintain activity against predicted resistance mutations

  • Target evolutionary constrained regions where mutations would compromise fitness

  • Develop dual-action compounds that inhibit SA1195.1 and secondary resistance pathways

• Delivery System Optimization:

  • Explore nanoparticle formulations to enhance delivery to infection sites

  • Develop prodrug approaches to improve penetration through the S. aureus cell wall

  • Investigate siderophore conjugation for active transport into bacterial cells

The most promising chemical scaffolds identified to date include hydroxamate derivatives that show IC50 values of 1.2-5.8 μM against recombinant SA1195.1 and MIC values of 8-32 μg/mL against clinical S. aureus isolates, including MRSA strains. These compounds demonstrate low cytotoxicity against human cell lines (CC50 >200 μM) and favorable pharmacokinetic profiles in preliminary animal studies. Second-generation derivatives with improved potency (sub-micromolar IC50) are currently being evaluated in animal infection models. The dual targeting of SA1195.1 and related tautomerases involved in stress response represents a novel therapeutic approach with potential to address antimicrobial resistance challenges .

What experimental approaches would best elucidate the role of SA1195.1 in S. aureus pathogenesis during different infection types?

To comprehensively elucidate the role of SA1195.1 in S. aureus pathogenesis across different infection types, researchers should implement the following experimental approaches:

• Infection Model Diversification:

  • Acute vs. chronic infection models: Compare SA1195.1 contribution in bacteremia, pneumonia, endocarditis, and implant-associated biofilm models

  • Host diversity studies: Evaluate phenotypes across immunocompetent, neutropenic, and diabetic animal models

  • Polymicrobial studies: Assess role in mixed infections with common co-pathogens (P. aeruginosa, C. albicans)

• In Vivo Temporal Profiling Techniques:

  • Implement in vivo transcriptomics to compare SA1195.1 expression across infection stages

  • Utilize IVIS imaging with reporter strains to track SA1195.1 promoter activity in real-time

  • Apply tissue-specific extraction techniques to isolate bacteria from different niches for ex vivo analysis

• Host Response Integration Strategies:

  • Single-cell RNA-seq of host cells interacting with wild-type vs. ΔSA1195.1 strains

  • Cytokine/chemokine profiling to identify specific immune pathways affected

  • Neutrophil extracellular trap (NET) formation quantification and bacterial survival assessment

• Metabolic Context Analysis:

  • Stable isotope labeling to track metabolic flux differences between wild-type and mutant during infection

  • Metabolomic analysis of infection sites to identify substrate availability across infection types

  • Ex vivo growth in tissue homogenates from different infection sites to simulate niche-specific conditions

• Systematic Virulence Factor Analysis:

  • Construct double mutants of SA1195.1 with major virulence regulators (agr, sarA, saeRS)

  • Apply Tn-seq to identify genes with synthetic phenotypes when combined with SA1195.1 deletion

  • Implement pooled infection models with barcode-tagged mutant libraries to assess competitive fitness